Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/06/2791626/36461/en/Voyager-Therapeutics-Announces-Selection-of-Development-Candidate-for-SOD1-Amyotrophic-Lateral-Sclerosis-Gene-Therapy-Program.html

LEXINGTON, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) — Voyager Therapeutics, Inc. (Nasdaq:VYGR), a biotechnology company dedicated to breaking through barriers in gene therapy and neurology, today announced that it has selected a lead development candidate for its superoxide dismutase 1 (SOD1)-mutated amyotrophic lateral sclerosis (ALS) gene therapy program. The Company anticipates filing an investigational new drug (IND) application with the Food and Drug Administration for the candidate in mid-2025.

Read more at globenewswire.com

Related news for (VYGR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.